Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance)

James J. Urbanic, Xiaofei Wang, Jeffrey A. Bogart, Thomas E. Stinchcombe, Lydia Hodgson, Steven E. Schild, Lyudmila Bazhenova, Olwen Hahn, Ravi Salgia, Everett E. Vokes
2018 International Journal of Radiation Oncology, Biology, Physics  
Purpose: Investigate the safety of accelerated hypofractionated radiotherapy (AHRT) with concurrent chemotherapy (CT) for inoperable stage III non-small-cell lung cancer (NSCLC). Patients and Methods: The primary objectives were to define the maximally tolerable course of accelerated radiotherapy and describe toxicities of therapy. Total radiotherapy remained at 60 Gy. The number of once daily fractions in each successive cohort was reduced. Cohort 1: 60 Gy 27 fx, Cohort 2: 60 Gy 24 fx, Cohort
more » ... : 60 Gy 22 fx, and Cohort 4 was 60 Gy 20 fx. Concurrent: weekly carboplatin AUC 2, paclitaxel 45 mg /m 2 . Consolidation: carboplatin AUC 6, paclitaxel 200 mg/m 2 q3 weeks × 2 cycles. MTD: Of 6 pts/cohort, ≤ 2 pts develop ≥ grade 3 toxicity and ≤1 pt develops ≥ grade 4 toxicity.
doi:10.1016/j.ijrobp.2018.01.046 pmid:29487024 pmcid:PMC6173195 fatcat:kfvpurqttjherej3ziy35iqzaa